Law Articles
To search for a particular term please use the following search box.
Law Topics
Click on a Topic to see available articles for that topic.
- Accidents
- Administrative Law
- Admiralty Law
- Articles
- Banking
- Bankruptcy Law
- Canon Law
- Case Law
- Civil Law
- Civil Rights
- Class Action Lawsuits
- Commercial Law
- Common Law
- Comparative Law
- Constitutional Law
- Consumer Law
- Contracts
- Corporate Law
- Courts
- Criminal Law
- Cyber Law
- Dispute Resolution
- Employment Law
- Equity
- Evidence
- Family Law
- Fiduciary Law
- General Practice
- Government
- Health Law
- Immigration Law
- Insurance Law
- Intellectual Property
- International Law
- Jurisprudence
- Labor Law
- Law and Economics
- Maritime Law
- Military Law
- Natural Law
- Personal Injury Law
- Philosophy of Law
- Property Law
- Public Law
- Real Estate Law
- Social Security
- Space Law
- Statutory Law
- Tax Law
- Traffic Law
- Trusts and Estates
- Water Law
Return to Law Dictionary Index
U.S. reviewing safety of Bayer heart-surgery drug
Wednesday, February 8, 2006, WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Wednesday urged doctors to limit the use of Bayer AG's Trasylol heart-surgery drug while the agency reviews research showing the medication heightened risks of heart attack, stroke and kidney problems.
"We're working to evaluate the potential risks and determine whether there is a need for further action," Dr. Steven Galson, Director of FDA's Center for Drug Evaluation and Research, said in a statement. "In the meantime, we advise providers to carefully assess the benefits and risks of the drug for their patients."
The FDA urged physicians to consider limiting the use of Trasylol to only those situations where the benefit of reducing blood loss during surgery outweighed the risks.
The FDA said it plans to hold an advisory committee meeting later this year to discuss existing data on the benefits and risks of the drug as well as to determine if more safety measures are needed.
Researchers reported last month in the New England Journal of Medicine that Trasylol doubled the risk of kidney failure and stroke and increased the chance of heart failure or heart attack by 55 percent.
German-based Bayer last month said the results were "not consistent with the more than 15 years of clinical data and experience Bayer has amassed on this drug."
A company spokesman in Germany said Bayer will cooperate with the FDA and other regulators. "We're analyzing the data we have on the drug," he said.
Bayer also said that it will send out an information letter in the next few days to heart surgeons, anesthetists and hospital pharmacists about Trasylol.
Shares of Bayer were down 31 cents to $40.01 in mid-afternoon trading on the New York Stock Exchange. (Additional reporting by Sitaraman Shankar in Frankfurt.)
Copyright � 2006 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
Full story at nlm.nih.gov